Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024


Continued preparations to launch LV portfolio...

Related Keywords

California , United States , Stanford University , American , America , Los Angeles , Agnieszka Czechowicz , Donaldb Kohn , Gaurav Shah , Company Cranbury , Dodge , Stanford University School Of Medicine , American Society Of Gene , Drug Administration , Rocket Pharmaceuticals , Youtube , Department Of Pediatrics , Rocket Pharmaceuticals Inc , Treatment Center , Alexion Pharmaceuticals , Division Of Hematology Oncology , University Of California , Arena Pharmaceuticals , Cell Therapy Program , Investor Relations Corporate Communications , Linkedin , Regeneron Pharmaceuticals , Corporate Communications At Krystal Biotech , European Medicines Agency , Nasdaq , Liberty Science Center , Fanconi Anemia , Danon Disease , Chief Executive Officer , Marketing Authorization Application , Biologics License Application , Leukocyte Adhesion Deficiency I , Qualified Treatment Center , Aaron Ondrey , Chief Financial Officer , Mirati Therapeutics , Meg Dodge , Vice President , Investor Relations , Corporate Communications , Rare Disease Day , Empire State , Pyruvate Kinase Deficiency , American Society , Cell Therapy , Annual Meeting , Gene Therapy , Pediatric Patients , Severe Pyruvate Kinase Deficiency , Global Study , Clinical Trials Spotlight Symposium , Clinical Investigator , Lentiviral Mediated Gene Therapy , Polyclonal Integration Patterns , Cell Based Gene Therapy Trials , Curative Medicine , Stem Cell Transplantation , Regenerative Medicine , Stanford University School , Lucile Packard Children , Hospital Stanford , Autologous Ex Vivo Lentiviral Gene Therapy , Favorable Safety Profile , Distinguished Professor , Molecular Genetics , Medical Pharmacology , America Global Healthcare Conference , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Months Ended March , Markets ,